期刊
VIRUSES-BASEL
卷 2, 期 6, 页码 1279-1305出版社
MDPI
DOI: 10.3390/v2061279
关键词
antiviral therapy; HBV therapy; nucleoside analogs; viral hepatitis
类别
资金
- VIRGIL European Network of Excellence on Antiviral Drug Resistance [LSHM-CT-2004-503359]
- FWO [G.0267.04]
While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据